Impact of Initial Heart Rate, Diastolic Pressure, and Pulse Pressure on Prognostic Outcomes in Heart Failure Patients with Mildly Reduced Ejection Fraction

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Date 2025 Jan 30

PMID 39881953

Authors

Hailong Hu

Zhican Liu

Jianping Zeng

Mingyan Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Heart rate, diastolic pressure, and pulse pressure are key modifiable factors influencing heart failure prognosis. While heart failure with mildly reduced ejection fraction (HFmrEF) is a distinct subgroup of heart failure, the prognostic impact of these hemodynamic parameters in this population remains unclear, necessitating focused investigation. This study aims to elucidate their effects on HFmrEF patient outcomes.

Methods: We retrospectively analyzed 1,653 hFmrEF patients treated at Xiangtan Central Hospital (2015-2020). Using decision tree classification, patients were categorized based on initial heart rate (≤77 bpm and >77 bpm). The ≤77 bpm group was further divided by pulse pressure (≤37 mmHg and >37 mmHg), and the >77 bpm group by diastolic pressure (≤63 mmHg, 63-100 mmHg, and >100 mmHg). Multivariate COX regression assessed mortality associations.

Results: With a median follow-up of 33 months, overall mortality was 21.7% for heart rates ≤77 bpm and 30.4% for >77 bpm. Multivariate COX regression showed that among patients with heart rates ≤77 bpm, those with pulse pressure >37 mmHg had a higher mortality risk than those with pulse pressure ≤37 mmHg (HR 3.184; 95% CI 1.008-10.058; p=0.048). For patients with heart rates >77 bpm, those with diastolic pressure 63-100 mmHg had a lower mortality risk compared to ≤63 mmHg (HR=0.652, 95% CI: 0.450-0.943, p=0.023), with the lowest risk in patients with diastolic pressure >100 mmHg (HR=0.370, 95% CI: 0.205-0.666, p=0.001).

Conclusion: This study highlights that HFmrEF patients with heart rates ≤77 bpm and pulse pressure ≤37 mmHg had the lowest mortality risk, while those with heart rates >77 bpm and diastolic pressure ≤63 mmHg faced the highest risk. These findings provide valuable insights for risk stratification and may guide personalized management of HFmrEF patients.

References

Savarese G, Lund L . Global Public Health Burden of Heart Failure. Card Fail Rev. 2017; 3(1):7-11. PMC: 5494150. DOI: 10.15420/cfr.2016:25:2. View

Angeli F, Reboldi G, Verdecchia P . Heart failure, pulse pressure and heart rate: Refining risk stratification. Int J Cardiol. 2018; 271:206-208. DOI: 10.1016/j.ijcard.2018.07.072. View

Matsuzawa Y . Is diastolic blood pressure key to detecting risk and preventing heart failure with preserved ejection fraction?. Hypertens Res. 2022; 46(2):534-536. DOI: 10.1038/s41440-022-01105-w. View

Anand I, Rector T, Cleland J, Kuskowski M, McKelvie R, Persson H . Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011; 4(5):569-77. DOI: 10.1161/CIRCHEARTFAILURE.111.962654. View

Chae C, Pfeffer M, Glynn R, Mitchell G, Taylor J, Hennekens C . Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999; 281(7):634-9. DOI: 10.1001/jama.281.7.634. View

Braunwald E . Biomarkers in heart failure. N Engl J Med. 2008; 358(20):2148-59. DOI: 10.1056/NEJMra0800239. View

Cheng R, Cox M, Neely M, Heidenreich P, Bhatt D, Eapen Z . Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014; 168(5):721-30. DOI: 10.1016/j.ahj.2014.07.008. View

Bohm M, Lloyd S, Ford I, Borer J, Ewen S, Laufs U . Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2016; 18(6):672-83. DOI: 10.1002/ejhf.493. View

Tavazzi L, Swedberg K, Komajda M, Bohm M, Borer J, Lainscak M . Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013; 15(11):1296-303. DOI: 10.1093/eurjhf/hft102. View

10.

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368. View

11.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M . 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of.... J Hypertens. 2018; 36(10):1953-2041. DOI: 10.1097/HJH.0000000000001940. View

12.

Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T . Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017; 19(10):1258-1269. DOI: 10.1002/ejhf.807. View

13.

Ziaeian B, Fonarow G . Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016; 13(6):368-78. PMC: 4868779. DOI: 10.1038/nrcardio.2016.25. View

14.

Lechat P, Hulot J, Escolano S, Mallet A, Leizorovicz A, Pochmalicki G . Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001; 103(10):1428-33. DOI: 10.1161/01.cir.103.10.1428. View

15.

Takahashi T, Shishido T, Watanabe K, Sugai T, Toshima T, Kinoshita D . Ventricular wall stress and silent myocardial damage are associated with pulse pressure in the general population. J Clin Hypertens (Greenwich). 2018; 20(9):1319-1326. PMC: 8031182. DOI: 10.1111/jch.13349. View

16.

Ferrari R, Fox K . Heart rate reduction in coronary artery disease and heart failure. Nat Rev Cardiol. 2016; 13(8):493-501. DOI: 10.1038/nrcardio.2016.84. View

17.

Komajda M, Carson P, Hetzel S, McKelvie R, McMurray J, Ptaszynska A . Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2010; 4(1):27-35. DOI: 10.1161/CIRCHEARTFAILURE.109.932996. View

18.

Franklin S, Gustin 4th W, Wong N, Larson M, Weber M, Kannel W . Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997; 96(1):308-15. DOI: 10.1161/01.cir.96.1.308. View

19.

Swedberg K, Komajda M, Bohm M, Borer J, Ford I, Dubost-Brama A . Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744):875-85. DOI: 10.1016/S0140-6736(10)61198-1. View

20.

Bohm M, Swedberg K, Komajda M, Borer J, Ford I, Dubost-Brama A . Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376(9744):886-94. DOI: 10.1016/S0140-6736(10)61259-7. View